94 reports of this reaction
2.9% of all ADENOSINE reports
#3 most reported adverse reaction
SUPRAVENTRICULAR TACHYCARDIA is the #3 most commonly reported adverse reaction for ADENOSINE, manufactured by Dalim Tissen. There are 94 FDA adverse event reports linking ADENOSINE to SUPRAVENTRICULAR TACHYCARDIA. This represents approximately 2.9% of all 3,219 adverse event reports for this drug.
Patients taking ADENOSINE who experience supraventricular tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUPRAVENTRICULAR TACHYCARDIA is a less commonly reported adverse event for ADENOSINE, but still significant enough to appear in the safety profile.
In addition to supraventricular tachycardia, the following adverse reactions have been reported for ADENOSINE:
SUPRAVENTRICULAR TACHYCARDIA has been reported as an adverse event in 94 FDA reports for ADENOSINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUPRAVENTRICULAR TACHYCARDIA accounts for approximately 2.9% of all adverse event reports for ADENOSINE, making it one of the most commonly reported side effect.
If you experience supraventricular tachycardia while taking ADENOSINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.